Skip to main content
Premium Trial:

Request an Annual Quote

GenomeDx, Janssen Partner to Test Tumor Genome Profile Database

NEW YORK (GenomeWeb) – GenomeDx said today that it has signed an agreement to test its Decipher GRID database of cancer genomic profiles with samples from prostate cancer clinical trials run by Janssen Pharmaceuticals.

Under the terms of the deal, GenomeDx will test the samples in order to evaluate the association of prognostic and predictive genomic signatures from the Decipher GRID platform — which includes more than 40,000 RNA expression profiles of urologic cancers — with clinical outcomes.

Additional terms were not disclosed.

"We are excited to work together with Janssen on this important research collaboration, which we believe will accelerate the discovery and development of genomic solutions for the treatment and management of high-risk prostate cancer," GenomeDx President and CSO Elai Davicioni said in a statement. "Using Decipher and GRID to leverage the knowledge derived from thousands of tumor genomic profiles to uncover novel predictors of treatment response with machine learning approaches will help realize our mutual goal of personalizing therapy for men suffering from this disease."

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.